Drug
Danoprevir clinical trials
Also written ASC08.
- studies test it
- 28
- open now
- 0
- in phase 3
- 2
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
28 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 7 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 7
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 1
Hoffmann-La Roche (20) · Ascletis Pharmaceuticals Co., Ltd. (7) · Huoshenshan Hospital (1)
Often tested with
Tested in the same studies.
Ritonavir (21) · Ribavirin (5) · Ravidasvir (4) · Peginterferon alfa-2a (3) · Mericitabine (2) · Escitalopram (1) · Cyclosporine (1) · Methadone (1)
Studies
Open first, then newest update. How each study uses danoprevir is read from its arms, and is right about nine times in ten.
Testing it · 28
- Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedPhase 3Ascletis Pharmaceuticals Co., Ltd.NCT03020082Written as Danoprevir
- Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT03020095Written as Danoprevir
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedPhase 2/3Ascletis Pharmaceuticals Co., Ltd.NCT03362814Written as Danoprevir
- Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionCompletedPhase 4Huoshenshan HospitalNCT04345276Written as Danoprevir+Ritonavir
- Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT03020004Written as Danoprevir
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03020134Written as Danoprevir
- Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03288636Written as Danoprevir
- Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03019991Written as Danoprevir
- A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic ImpairmentCompletedPhase 1Hoffmann-La RocheNCT01185873Written as danoprevir
- A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01418274Written as danoprevir
- A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01483729Written as danoprevir
- A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1CompletedPhase 1Hoffmann-La RocheNCT01185860Written as danoprevir
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01514968Written as danoprevir
- A Study on the Interaction Between Danoprevir/Ritonavir and MethadoneCompletedPhase 1Hoffmann-La RocheNCT01389544Written as danoprevir
- A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without CirrhosisCompletedPhase 2Hoffmann-La RocheNCT01749150Written as danoprevir + ritonavir
- A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01592318Written as danoprevir
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedPhase 2Hoffmann-La RocheNCT01278134Written as danoprevir
- A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C PatientsCompletedPhase 1Hoffmann-La RocheNCT00801255Written as danoprevir
- A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01519336Written as danoprevir
- A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01588002Written as danoprevir
See all 28 studies that test danoprevir →
Given in every arm · 5 — danoprevir is usual care beside what is tested
- ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based TreatmentCompletedPhase 2Hoffmann-La RocheNCT01628094Written as RO5190591
- A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01392755Written as danoprevir
- A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01331850Written as danoprevir
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor TreatmentWithdrawnPhase 2Hoffmann-La RocheNCT01579019Written as danoprevir
- A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated CirrhosisCompletedPhase 2Hoffmann-La RocheNCT01483742Written as danoprevir
Codes
What other systems call danoprevir · ClinicalTrials.gg INT005742
- MeSH (NLM) C553752danoprevirOne source NLM
- UNII (FDA) 911Z9PCQ5FDANOPREVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27271364danoprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171872DanoprevirOne source FDA
- DrugBank DB11779One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553752 | danoprevir | One source NLM |
| UNII (FDA) | 911Z9PCQ5F | DANOPREVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27271364 | danoprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171872 | Danoprevir | One source FDA |
| DrugBank | DB11779 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.